Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2020

View Archived Issues

Engineered brown fat cells improve blood sugar control

For organs, rejuvenation helps transplantation

Cartesian initiates first-in-human study of Descartes-30 in patients with ARDS and COVID-19

REPAVID-19 study of reparixin in severe COVID-19 pneumonia approved in Brasil

Aligos Therapeutics divulges new antivirals

DE Shaw Research patents Abeta aggregation inhibitors

Researchers from Czech Republic present compounds for neurodegeneration

LNP-023 demonstrates efficacy, both as add-on and monotherapy, in patients with PNH

Agios Pharmaceuticals identifies PKM2 and PKLR activators

Starpharma creates long-acting, water-soluble version of remdesivir

PTC Therapeutics discovers new compounds targeting mRNA splicing machinery

Janssen discontinues development of pimodivir for influenza A

CanSino announces start of phase III trial with Ad5-nCoV vaccine for COVID-19

New therapeutic target for blood sugar control identified

Transmembrane domain-deficient STING protein developed for cGAMP delivery

BIAL presents phase I data on the dopamine beta-hydroxylase inhibitor zamicastat

Nocion begins healthy volunteer study of NOC-100 for cough

Health Canada clears initiation of phase III trial of Pulmonem's reformulated dapsone for COVID-19

First-in-human data presented for TQA-3526

Abivax reports 2-year data from phase IIa maintenance study of ABX-464 in ulcerative colitis

HMPL-453 enters phase II study for advanced intrahepatic cholangiocarcinoma

New phase I/II trial evaluates Treadwell's CFI-402411 in solid tumors

Sanofi and GSK advance adjuvanted COVID-19 vaccine into phase I/II evaluation

Enesi partners with University of Adelaide to develop thermostable solid dose DNA Zika vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...